Premium
Real‐world data on the efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis
Author(s) -
Papadavid E.,
Rompoti N.,
Theodoropoulos K.,
Kokkalis G.,
Rigopoulos D.
Publication year - 2018
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/jdv.14832
Subject(s) - apremilast , medicine , psoriasis , dermatology life quality index , psoriatic arthritis , psoriasis area and severity index , adverse effect , dermatology , discontinuation , clinical endpoint , clinical trial
Background Psoriasis is a chronic inflammatory skin disease, which requires long‐term, safe and effective treatment. Apremilast, a small‐molecule PDE 4 inhibitor, has been introduced as psoriasis (and psoriatic arthritis) treatment in Europe in 2015. Objective We analysed and report the efficacy and safety of apremilast in the first 51 patients with psoriasis that have undergone treatment with this novel small molecule in our outpatient clinic. Method Our primary endpoint was the evaluation of clinical response to apremilast according to the percentage of Psoriasis Area Severity Index ( PASI ) reduction (Δ PASI ) at 16 weeks after treatment initiation. Secondary endpoints were the evaluation at week 16 of (i) PASI ; (ii) Dermatology Life Quality Index ( DLQI ); (iii) Physician Global Assessment ( PGA ); (iv) Psoriasis Scalp Severity Index ( PSSI ); and (v) the percentage of patients who achieved Δ PASI 50, Δ PASI 75, Δ PASI 90 and Δ PASI 100; (vi) adverse events ( AE ); (vii) reasons for drug discontinuation; and (viii) drug survival. Results About 59.3% of the patients who remained on apremilast achieved at least Δ PASI 75 at week 16, while 11.1% achieved combined 50% ≤ PASI < 75% and DLQI ≤ 5 (satisfactory response) adequate enough to maintain treatment. Five patients (18.5%) also achieved Δ PASI 100. Patients discontinued apremilast (28%), mostly during the first 4 weeks due to adverse events (12%) with gastrointestinal symptoms being the most common, and later due to lack of efficacy (16%). A statistically significant improvement of PASI , DLQI , PGA and PSSI scores was observed after 4 and 16 weeks of treatment relative to pretreatment measurements. Conclusion Apremilast is a safe and efficacious treatment for psoriasis patients as it produces Δ PASI 75 and Δ PASI 50 responses combined with DLQI ≤ 5 in 16 weeks in 70.4% of the patients. These results, from a real‐world setting, confirm the efficacy and safety of apremilast which has been demonstrated in large phase III clinical trials.